Reteplase biosimilar - Reliance Life Sciences

Drug Profile

Reteplase biosimilar - Reliance Life Sciences

Alternative Names: MiRel; R TPR 004

Latest Information Update: 16 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Reliance Life Sciences
  • Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
  • Mechanism of Action Plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • No development reported Stroke

Most Recent Events

  • 16 Dec 2015 No development reported - Phase-II for Stroke in India (IV)
  • 06 May 2013 Phase-II clinical trials in Stroke in India (IV)
  • 31 Dec 2009 Launched for Myocardial infarction in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top